Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.
Koshiro KanaokaTaku NishidaYoshitaka IwanagaMichikazu NakaiReina Tonegawa-KujiYuichi NishiokaTomoya MyojinKatsuki OkadaTatsuya NodaKengo F KusanoYoshihiro MiyamotoYoshihiko SaitoTomoaki ImamuraPublished in: European heart journal (2023)
This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- heart failure
- human health
- percutaneous coronary intervention
- stem cells
- risk assessment
- venous thromboembolism
- coronary artery disease
- mitral valve
- cell therapy
- left ventricular
- acute coronary syndrome
- protein kinase
- replacement therapy